

NeuroMetrix, Inc. (NASDAQ: NURO)

NEWS MEDIA FACT SHEET

OVERVIEW

NeuroMetrix is a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders. It is presently focused on diabetic neuropathies which affect over 50% of people with diabetes. NeuroMetrix has leading R&D capability through its engineering team which has worked together for over a decade in developing neuro-stimulation and detection technologies.

MARKETS

There are over 300 million people in the world with diabetes and over 26 million in the U.S. The most common complication of diabetes is diabetic peripheral neuropathy (DPN) which, if left untreated, triggers foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at \$14 billion in the U.S. The company markets the SENSUS™ Pain Management System for treating chronic pain, and also markets the NC-stat® DPNCheck® device, which is used to detect diabetic neuropathy at an early stage and to guide treatment.

BUSINESS & PRODUCTS

The company's business model is based on sophisticated nerve stimulation technologies that employ FDA-cleared medical devices, consumable electrodes and other accessories. It has three product lines in the market: **SENSUS™ Pain Management**, **NC-stat® DPNCheck®**, and **ADVANCE™ NCS System**.

SENSUS Pain Management is a lightweight, wearable, non-invasive electrical nerve stimulator that offers patients a fast-acting, non-narcotic option for relief from chronic pain. The most common cause of such pain is painful diabetic neuropathy (PDN), which affects up to 5 million people in the U.S. alone. SENSUS was specifically designed for PDN patients. It can be prescribed as a compliment to pain medications and worn during the day while active, or at night while sleeping.



SENSUS Pain Management

NC-stat DPNCheck is a fast, accurate and quantitative point-of-care test for diabetic peripheral neuropathy. The DPNCheck test addresses an unmet medical need for better and more cost-effective screening, diagnosing and monitoring of DPN. The device measures sural nerve conduction velocity and response amplitude which are standard biomarkers for DPN. Currently available point-of-care testing methods are subjective and detect advanced DPN when it may be too late for effective treatment.



NC-stat DPNCheck

ADVANCE NCS System is a general purpose nerve testing system for performing nerve conduction studies (NCS). Using ADVANCE, a physician can run traditional nerve tests, get immediate results and prepare thorough test reports. The technology simplifies testing and reporting thereby expediting diagnosis and improving patient care for indications including diabetic neuropathy, low back pain, and carpal tunnel syndrome (CTS).



ADVANCE NCS System

R&D PIPELINE

NeuroMetrix has a promising pipeline which includes a second generation SENSUS with a thinner profile design and improved functionality, and an over-the-counter version of SENSUS for retail markets. Other research-stage products include devices for fall prevention, foot ulcer healing, and restless leg syndrome.

MANAGEMENT

Shai N. Gozani, M.D., Ph.D.

President, Chief Executive Officer and Director

Dr. Gozani founded NeuroMetrix in 1996 and currently serves as Chairman of the board of directors and as President and Chief Executive Officer. Prior to forming the company, Dr. Gozani completed a neurophysiology research fellowship in the laboratory of Dr. Gerald Fischbach at Harvard Medical School. Dr. Gozani holds a B.A. degree in Computer Science, an M.S. degree in Biomedical Engineering and a Ph.D. in Neurobiology, from the University of California, Berkeley. He also received an M.D. from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology at M.I.T.

Thomas T. Higgins

Senior Vice President and Chief Financial Officer

Mr. Higgins has a broad set of financial management and operations skills including extensive international experience. Prior to joining NeuroMetrix, Mr. Higgins was Chief Financial Officer at Caliper Life Sciences Inc., and before Caliper, he was Chief Financial Officer at V.I. Technologies, Inc. Mr. Higgins served at Cabot Corporation in various senior finance and operations roles including President of DISTRIGAS of Massachusetts Corporation, and prior to that he was Vice President and General Manager responsible for Cabot's Asia Pacific carbon black operations. Mr. Higgins began his career with Price Waterhouse. He holds a B.B.A. with honors from Boston University.



Dr. Shai Gozani (left) & Tom Higgins (right)

CONTACT

Mr. Thomas Higgins
Chief Financial Officer
NeuroMetrix, Inc.
62 4th Avenue
Waltham, MA 02451 USA